Comparison of nystatin and fluconazole effects in the healing of oral candidiasis in immunocompromised individuals
Sažetak
Oral candidiasis is a common fungal infection of the mouth in immunocompromised individuals. It occurs when it meets ideal conditions for breeding and represents an obstacle to patients. Candida treatment consists of solving the contributing factors and in addition application of certain antifungal drugs, including nystatin and fluconazole. Evaluation of the efficacy of these drugs is important in narrowing the choice of drugs in the selection therapy. The purpose of this study was to compare the efficacy of nystatin and fluconazole in the treatment of candida albicans. For this study two databases were searched: PubMed and SCIndex - in order to find papers that are appropriate in their content in making the conclusion which meet the criteria of validity and significance. In search of papers were used different combinations of keywords based on the obtained studies that have been dealt with comparing one of these two antifungal drugs. After analysing all of these studies, a number of studies that have fulfilled the criteria of validity and significance has been reduced to 8. Results of comapared studies have shown that the advantage in the treatment of oral candidiasis has fluconazole. The use of fluconazole in the treatment of fungal infection Candida albicans is completely safe and patients treated with this drug showed a longer period without recurrence compared to patients treated with nystatin.
Reference
Čanković М, Bokor-Bratić М. Infekcija kandidom albikans kod bolesnika sa oralnim planocelularnim karcinomom. Vojnosanitetski pregled 2010; 67(9): 766-770.
Janković Lj. Oralna Medicina, Zavod za udzbenike i nastavna sredstva Beograd, 2007. Poglavlje 8, Oralne manifestacije gljivičnih infekcija. 126-131.
Janković S. Farmakologija i toksikologija za stomatologe. Fakultet Medicinskih Nauka Kragujevac, 2011.
McEvoy, G.K. American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2006.
American Medical Association, AMA Department of Drugs, AMA Drug Evaluations. 3rd ed. Littleton, Massachusetts: PSG Publishing Co., Inc., 1977.
Lumbreras C, Cuervas-Mons V, Jara P, del Palacio A, Turrión VS, Barrios C et al. Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. Journal Infectious Diseases 1996; 174(3): 583-8.
Nenoff P, Krüger C, Ginter-Hanselmayer G, Tietz HJ. Mycology - an update part 2: dermatomycoses: clinical picture and diagnostics. J Dtsch Dermatol Ges. 2014; 12:749–77.
Picciani BL, Michalski-Santos B, Carneiro S, Sampaio AL, Avelleira JC, Azulay DR, et al. Oral candidiasis in patients with psoriasis: correlation of oral examination and cytopathological evaluation with psoriasis disease severity and treatment. J Am Acad Dermatol. 2013; 68:986–91.
Miller DJ. Diagnosis and management of Candida and other fungal infections of the head and neck. Curr Infect Dis Rep. 2002;4:194–200.
Cuenca-Estrella M, Verweij PE, Arendrup MC, ArikanAkdagli S, Bille J, Donnelly JP et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect. 2012;18(7):9–18.
Pons V, Greenspan D, Lozada-Nur F, McPhail L, Gallant JE, Tunkel A et al. Oropharyngeal Candidiasis in Patients with AIDS: Randomized Comparison of Fluconazole Versus Nystatin Oral Suspensions. Clinal Infectious Diseases 1997; 24(6): 1204-7.
Pagani JL, Chave JP ,Casjka C, Glauser MP, Bille J. Efficacy, tolerability and development of resistance in HIV-positive patients treated with fluconazole for secondary prevention of oropharyngeal candidiasis: a randomized, double-blind, placebo-controlled. Journal Antimicrobial Chemotherpy 2002; 50(2): 231-40.
Hamza OJ, Matee MI, Brüggemann RJ, Moshi MJ, Simon EN, Mugusi F et al. Single-Dose Fluconazole versus Standard 2- Week Therapy for Oropharyngeal Candidiasis in HIV-Infected Patients. Clinal Infectious Diseases 2008; 47(10): 1270-6.
Groll AH, Just-Nuebling G, Kurz M. Muellera C, Nowak-Goettla U, Schwabe D et al. Fluconazole versus nystatin in the prevention of candida infections in children and adolescents undergoing remission induction or consolidation chemotherapy for cancer. Journal Antimicrobial Chemotherpy 1997; 40(6): 855-62.
Laverdière M, Rotstein C, Bow EJ, Roberts RS, Ioannou S, Carr D et al. Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients. Journal Antimicrobial Chemotherpy 2000; 46(6): 1001-8.
Gøtzsche PC, Johansen HK. Prevention and treatment of fungal infections in severely immunodepressed patients with nystatin. Cochrane Database Syst Rev. 2002;(4):CD002033.
Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis: results of two phase 3 trials. N Engl J Med. 2014;371:326–38.